INACTIVATED HEPATITIS-A VACCINE - LONG-TERM ANTIBODY PERSISTENCE

During the clinical development of safe, Melt tolerated and immunogeni c vaccines against hepatitis A the persistence of protective antibodie s was estimated based on relatively short observation periods of 18 mo nths to 3 years. We report here on longterm persistence of antibodies in volunteers who participated in one of the early clinical trials on inactivated hepatitis A candidate vaccines. In a randomised trial thre e groups of altogether 110 healthy adults, initially hepatitis A virus (HAV) seronegative persons were vaccinated with an inactivated hepati tis A vaccine according to the schedule 0-1-2-12 months One group rece ived 180 ELISA units, one group 360, and one 720 ELISA units per dose, Blood samples were taken prior to the first vaccination and at months 1, 2, 3, 4, 6, 12, 13, 18, 24, 36 and 84, The decrease of antibodies was characterized by two disappearance rates: a rapidly decreasing com ponent and a slower decreasing one becoming predominant ca 12 months a fter booster vaccination. The disappearance of antibodies could be dec ribed by a two-component model which holds for t greater than or equal to 13 months. The estimated disappearance rates for the slow componen t (annual decrease) was found to be 11 and 13% for the 180 and 360 El. U groups, respectively (the 720 El. U group showed no decline, which was probably due to the small sample size). The estimated persistence of antibodies within protective range varied between 24 and 47 years d epending on individual titres reached at month 13 and vaccination dose . (C) 1997 Elsevier Science Ltd.